Teacher Retirement System of Texas Cuts Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Teacher Retirement System of Texas cut its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 29.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,272 shares of the company's stock after selling 30,470 shares during the period. Teacher Retirement System of Texas' holdings in Elanco Animal Health were worth $759,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ELAN. FMR LLC boosted its stake in shares of Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after purchasing an additional 37,022,891 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 6.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after acquiring an additional 1,074,274 shares during the last quarter. Shapiro Capital Management LLC grew its holdings in Elanco Animal Health by 7.5% during the 4th quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock worth $149,640,000 after acquiring an additional 862,900 shares during the period. Magnetar Financial LLC raised its position in shares of Elanco Animal Health by 13.7% in the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after acquiring an additional 1,454,082 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Elanco Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock valued at $99,102,000 after purchasing an additional 312,165 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ELAN shares. Stifel Nicolaus raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a report on Thursday. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Stock Up 3.1%

Shares of NYSE:ELAN traded up $0.45 during trading on Thursday, reaching $14.96. 4,998,781 shares of the stock were exchanged, compared to its average volume of 5,054,610. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $15.78. The stock has a fifty day moving average of $13.71 and a two-hundred day moving average of $11.75. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The firm has a market cap of $7.43 billion, a price-to-earnings ratio of 20.21, a price-to-earnings-growth ratio of 2.86 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business posted $0.34 EPS. Elanco Animal Health's quarterly revenue was down 1.0% on a year-over-year basis. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.